血清25(OH)D判断糖尿病合并NAFLD患者继发进展性肝纤维化的应用价值

肝脏 ›› 2020, Vol. 25 ›› Issue (8): 810-812.

血清25(OH)D判断糖尿病合并NAFLD患者继发进展性肝纤维化的应用价值

文琼花, 唐敏云, 魏玉

571500 海南万宁市人民医院检验科(文琼花,唐敏云),感染科(魏玉)

收稿日期:2019-10-03 出版日期:2020-08-31 发布日期:2020-09-04

The application value of serum 25(OH)D in the evaluation of progressive liver fibrosis in diabetic patients with nonalcoholic fatty liver disease

WEN Qiong-hua, TANG Min-yun, WEI Yu

Department of Laboratory Medicine, Wanning People's Hospital, Hainan 571500, China

Received:2019-10-03 Online:2020-08-31 Published:2020-09-04

摘要/Abstract

摘要： 目的研究血清25-羟维生素D[25(OH)D]判断2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者继发进展性肝纤维化的价值。方法回顾性分析2015年5月至2019年5月于我院收治的265例T2DM合并NAFLD患者的临床资料,分析其进展性肝纤维化发生情况,并采用多因素logistic回归分析法分析患者继发进展性肝纤维化的独立影响因素,判断血清25(OH)D对进展性肝纤维化的预测价值。结果 265例患者中有80例(30.19%)继发进展性肝纤维化。除年龄、糖尿病病程、体质量指数、血红蛋白、白蛋白、ALT、AST/ALT、血肌酐、胱抑素C、24 h尿微量白蛋白外,血清25(OH)D亦是其继发进展性肝纤维化的独立影响因素(P<0.05),且其对进展性肝纤维化有一定预测价值,曲线下面积为0.831。结论血清25(OH)D在T2DM合并NAFLD患者继发进展性肝纤维化评估中具有重要作用。

关键词: 25-羟维生素D, 2型糖尿病, 非酒精性脂肪性肝病, 进展性肝纤维化

Abstract: Objective To study on the application value of serum 25-hydroxyvitamin D [25(OH)D] in the evaluation of progressive liver fibrosis in patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Methods The clinical data of 265 T2DM patients with NAFLD enrolled in our hospital from May 2015 to May 2019 were retrospectively analyzed for their status of liver fibrosis progression. Multi-factor Logistic regression analysis was applied to investigate the independent factors, and to determine the predictive value of serum 25(OH)D for progressive liver fibrosis. Results Of the 265 patients, 80 (30.19%) had progressive liver fibrosis. In addition to age, the course of diabetes mellitus, body mass index, hemoglobin, albumin, alanine aminotransferase, ratio of aspartate aminotransferase and alanine aminotransferase, serum creatinine, cystatin C and 24-hour urinary microalbumin, serum 25(OH)D was also an independent predictive factor associated with liver fibrosis progression (P<0.05) with the area under curve (ROC)of 0.831. Conclusion Serum 25(OH)D plays an important role in the assessment of progressive liver fibrosis in patients with T2DM accompanied with NAFLD.

Key words: 25-hydroxyvitamin D, Type 2 diabetes mellitus, Nonalcoholic fatty liver disease, Progressive liver fibrosis

文琼花, 唐敏云, 魏玉. 血清25(OH)D判断糖尿病合并NAFLD患者继发进展性肝纤维化的应用价值[J]. 肝脏, 2020, 25(8): 810-812.

WEN Qiong-hua, TANG Min-yun, WEI Yu. The application value of serum 25(OH)D in the evaluation of progressive liver fibrosis in diabetic patients with nonalcoholic fatty liver disease[J]. Chinese Hepatolgy, 2020, 25(8): 810-812.

[1]	邓永红, 王璟, 王晓莉, 李文霞, 熊万春. 雄激素水平变化对多囊卵巢综合征伴非酒精性脂肪性肝病患者的影响[J]. 肝脏, 2020, 25(6): 622-624.
[2]	张彬, 张立新, 马婷婷, 苗江虎, 王涛. 2型糖尿病患者血清甲状腺激素水平变化及其与非酒精性脂肪肝的关系[J]. 肝脏, 2020, 25(5): 519-521.
[3]	刘婕, 常毅娜, 曹书义. HIIT对NAFLD合并糖尿病的肥胖患者内脏脂质、胰岛素抵抗及健康相关生活质量的影响[J]. 肝脏, 2020, 25(4): 426-428.
[4]	宁惠明, 徐燕华. 非酒精性脂肪性肝病患者血清视黄醛结合蛋白4的变化及临床意义[J]. 肝脏, 2020, 25(4): 429-432.
[5]	徐丹, 戴秀丽, 张晓梅, 郝咏梅. 2型糖尿病并发非酒精性脂肪性肝病患者血清趋化素、细胞角蛋白18 M30、细胞角蛋白18 M65水平及其临床意义[J]. 肝脏, 2020, 25(1): 46-49.
[6]	王倩, 李秀丽, 杨楠, 王秀萍, 段锦花. GLP-1受体激动剂治疗2型糖尿病合并脂肪肝患者的效果[J]. 肝脏, 2019, 24(9): 1060-1062.
[7]	焦栓林, 秦建增, 杜世奇, 赵晓蕊, 张玉华, 欧阳洪, 胡艳玲. 双环醇联合水飞蓟宾治疗非酒精性脂肪性肝病疗效观察[J]. 肝脏, 2019, 24(9): 1068-1069.
[8]	孙琦, 苏畅, 刘绍群, 雷铭, 沈晓东, 饶荣华, 曹奕鸥. 抗生素联合胸腺肽α1治疗糖尿病合并细菌性肝脓肿的疗效[J]. 肝脏, 2019, 24(9): 1070-1071.
[9]	龙柳艳, 韦晓谋. 非酒精性脂肪性肝病患者血清Betatrophin水平评估病情严重程度的应用价值[J]. 肝脏, 2019, 24(8): 933-935.
[10]	许书慧, 郑地明, 钟瑛, 曾少芬. 恩替卡韦对乙型肝炎合并2型糖尿病患者肾功能的影响[J]. 肝脏, 2019, 24(6): 706-708.
[11]	汤群, 欧强. PTX3在非酒精性脂肪肝患者血清中的表达及与肝纤维化评分的相关性[J]. 肝脏, 2019, 24(2): 175-177.
[12]	张丹琴, 杨帆, 李胜保. 非酒精性脂肪性肝病患者血清TLR4、IL-10、IL-22与肠道菌群的相关性[J]. 肝脏, 2019, 24(12): 1432-1434.
[13]	张明芳, 郝凯峰, 仲广生, 陈秀春. 非酒精性脂肪性肝病与乳腺癌的相关性研究[J]. 肝脏, 2019, 24(11): 1293-1295.
[14]	林先强, 符清宇, 沙丹. 肥胖儿童非酒精性脂肪性肝病的危险因素分析[J]. 肝脏, 2019, 24(11): 1306-1309.
[15]	田长印, 贾晓黎, 李梅, 王媛. 骨代谢指标在中年人群非酒精性脂肪性肝病患者中的表达及其相关性[J]. 肝脏, 2019, 24(10): 1138-1140.